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Background: The utility of apolipoprotein E (ApoE)
type as an indicator of genetic susceptibility to Alzhei-
mer disease (AD) depends on the reliability of typing.
Although ApoE protein isoform phenotyping is gener-
ally assumed equivalent to genotyping from DNA,
phenotype-genotype differences have been reported.
Methods: ApoE genotype and phenotype results were
examined for 3564 older (ages 71–93 years) Japanese-
American male participants of the Honolulu-Asia Aging
Study, an ongoing population-based study of aging and
dementia.
Results: Both methods demonstrated similar associa-
tions of ApoE type with AD: a direct association with
ApoE4 and a less dramatic inverse association ApoE2.
Advanced age did not appear to influence the
ApoE4-AD association. The association with AD among
ApoE4 homozygotes [odds ratio (OR) 5 14.7] was higher
than expected based on an observed OR of 2.0 in
heterozygotes. Phenotype-genotype nonconcordance
was more frequent for ApoE2 than for ApoE4. The
ApoE2 phenotype occurred at a frequency of 7.9% vs a
genotype frequency of 4.9%, corresponding to a proba-
bility of 56% that an individual with ApoE2 phenotype
had the same genotype.
Conclusions: Whereas E4 and E2 phenotypes and geno-
types were comparably associated with AD, neither
method would be expected to substantially improve the
efficiency of case finding in the context of population
screening beyond prediction based on age and educa-
tion. Nonconcordance of phenotype and genotype was
substantial for E2 and modest for E4 in this population.
The ApoE4-AD association was independent of age.
© 2000 American Association for Clinical Chemistry
Apolipoprotein E (ApoE)6 plays a role in the transport
and redistribution of lipids, including cholesterol. Of the
three common isoforms of this glycoprotein (E2, E3, and
E4), E3 is by far the most common. Isoform E4 is associ-
ated with higher plasma concentrations of cholesterol,
cardiovascular disease, and Alzheimer disease (AD) (1–
4). The corresponding genetic alleles, which are found on
chromosome 19 (e2, e3, e4), account for 99% of the genetic
variance (5 ), and involve differences in codons 112 and
158.
The ApoE e4 allele has been shown to be associated
with AD in African-American, European, Japanese, and
Asian-ancestry populations (6–15). Increased AD risk is
associated with either one or two copies of the e4 allele
and has led some to advocate e4 genotyping for diagnos-
tic support in early dementia or as an adjunct to the
differential diagnosis of dementia (9, 16, 17). Other re-
ports have suggested that ApoE2 is protective for AD
(18, 19). This report addresses the reliability and compa-
rability of ApoE phenotyping and genotyping, and the
implications of using these two methods for epidemiolog-
ical studies, population screening, and patient care. There
have been previous reports of inconsistencies between
ApoE genotypes and phenotypes, possibly related to
methodological or other problems (20–26). One possibil-
ity is that posttranslational protein glycation might influ-
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ence accurate characterization of the phenotype. Potential
inconsistencies between ApoE genotyping and phenotyp-
ing are important considerations in assessing the utility of
genetic testing for ApoE in epidemiological studies and in
patient care. Although several statements about the use-
fulness of ApoE testing have been made, these include no
mention of the possibility of laboratory errors (27–32).
This report aims to answer the following questions: (a)
Are results of phenotyping and genotyping of ApoE the
same? (b) Is the association of ApoE with AD different for
phenotype and genotype? (c) What are the consequences
of any difference in ApoE typing for specific applications
(research, screening, patient care)?
Data and Methods
honolulu-asia aging study cohort
The Honolulu-Asia Aging Study (HAAS) cohort consists
of Japanese-American men born from 1900 through 1919
and living on Oahu, Hawaii when the study began. Of
men followed since 1965, 3734 received evaluations for
cognitive function and dementia during the 1991–1993
examination cycle (33–35). Subjects were fully informed
regarding participation in the study and provided in-
formed consent. Interviews and testing were carried out
by trained interviewers, either in the research center or at
the subjects’ homes or nursing homes, in the subjects’
preferred language [Japanese (12%) or English].
dementia
Dementia was assessed using Diagnostic and Statistical
Manual of Mental Disorders (DSM-III-R) diagnostic criteria
(36 ) by a panel consisting of the study neurologist and at
least two other physicians with expertise in geriatric
medicine. Criteria of the National Institute of Neurologi-
cal and Communicative Disorders-Alzheimer’s Disease
and Related Dementias Association were similarly ap-
plied for the diagnosis of probable or possible AD. A total
of 105 cases included 61 individuals classified as having
probable AD, 6 classified as having possible AD with no
other cause apparent, and 38 classified as having possible
AD judged the primary cause of the dementia, but with
another contributing cause also recognized. Odd ratios
(ORs) were calculated by comparing AD patients with the
rest of the HAAS sample.
laboratory determinations of ApoE phenotype
and genotype
ApoE phenotyping and genotyping were done on plasma
and buffy coat preparations separated from anticoagu-
lated blood within 2 h of collection and then frozen and
held at 270 °C until thawed for this use. Phenotyping was
done at the Northwest Lipid Research Laboratory, Seattle,
under the direction of one of the authors (S.M.), using a
modification of the method described by Kataoka et al.
(37 ). Briefly, 10 mL of plasma sample was incubated with
dithiothreitol (0.7 g/L) and Tween 20 (2.5 mL/L) for 15
min in preparation for monodimensional isoelectric focus-
ing. Flatbed gels of 5% polyacrylamide containing am-
pholytes (pH range 4.0–8.0) and 3 mol/L urea were
prepared, placed in an LKB Electrophor electrofocusing
unit, and prefocused by applying constant power of 20 W
for 15 min, with 1 mol/L NaOH and 1 mol/L phosphoric
acid as cathode and anode buffers, respectively. Plasma
samples adsorbed onto filter strips were applied on the
gel ;15 mm from the cathode. Known samples of the
common phenotypes were included with unknowns in
each gel. A constant power of 20 W for 30 min was
applied to allow samples to enter the gel. Sample wicks
were removed, and sample proteins were focused by
further power application for 90 min. Protein fractions in
the gel were eluted and transferred to a nitrocellulose
filter by overnight passive capillary adsorption. The ni-
trocellulose filter containing the protein bands was incu-
bated for 60 min in Tris-buffered saline (0.25 mol/L NaCl,
0.03 mol/L Tris-HCl, pH 8.0) containing 20 g/L nonfat
milk. The filter was exposed for 60 min to a monospecific
goat anti-human ApoE antibody (Inkstar), washed in
Tris-buffered saline, and reacted with a second antibody,
goat anti-rabbit conjugated with horseradish peroxidase
(Kirkegaard & Perry Laboratories). After several wash-
ings, the banding patterns on the filter were visualized
using an ECL chemiluminescence system (Amersham
Pharmacia Biotech), and a permanent record of the results
was made by exposing an autoradiographic film (Kodak).
During the early phases of the study, the procedure
was validated by running 200 samples in double-blind
fashion. Confirmed samples were included as quality
controls in subsequent analyses. Data entry and final
types were checked regularly by a second person. Pheno-
types for a panel of ;20 samples identified as nonconcor-
dant with genotype were independently confirmed at a
second laboratory. Although it may be possible to identify
the ApoE5 and ApoE7 phenotype patterns on gels such as
those used for this study, samples of these isoforms were
not ordinarily included as known positives in gels, and
neither the antibody reagents nor the methods have been
evaluated to determine whether these isoforms would
have been identified.
ApoE genotyping was done at Duke University under
the direction of one of the authors (A.S.). Genomic DNA
was extracted from peripheral blood leukocytes (buffy
coat samples heavily contaminated with erythrocytes)
using Puregene kits (Gentra Systems) according to the
manufacturer’s protocol for blood. ApoE gene amplifica-
tion and typing were performed as described by Saunders
et al. (7 ) with the exception that reactions were nonradio-
active and restriction digest fragments were visualized
using a fluorimager after SYBR Green staining. Efforts to
minimize human error included assigning sample-spe-
cific barcodes to all buffy coat samples, aliquots, and
extracted DNA and using these to track the sample
through DNA extraction, PCR set up, and reading. Risk of
pipetting and transferring errors were minimized by
rigorous standardization of procedures for aliquoting
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DNA samples and loading gels, and by spacing of sam-
ples and controls (water, ApoE calibrators, molecular
weight markers). Gels were read and genotypes tran-
scribed by two persons independently, with correspon-
dence checked after data entry.
statistical analysis methods
Because ApoE2, -3, and -4 alleles and the isoforms of a
pair can be considered independent of each other, our
analysis is based both on allele and isoform frequencies
(given two observations per person), and on gene pairs
and persons (where each person is one observation and
can be homo- or heterozygous). ORs were calculated by
logistic regression, controlling for age and education.
Confidence intervals are 95% confidence intervals, and
significance testing is at the 5% level, unless otherwise
stated.
Multivariate logistic regression analyses to evaluate
associations of E2 and E4 ApoE alleles or isoforms with
AD (Table 4) were carried out as a series of four separate
models. The dependent variable was the dichotomous
(present or not present) diagnosis of AD, based on Na-
tional Institute of Neurological and Communicative Dis-
orders-Alzheimer’s Disease and Related Dementias Asso-
ciation diagnostic criteria for probable or possible AD.
This included the 105 cases described above and excluded
other cases of possible AD in which the most important
cause of dementia was not thought to be AD. All regres-
sion models included age (in single years) and education
(as single years of schooling completed) as covariates. To
assess possible interactions of ApoE type with age or
education, all possible two-variable products of the E2 or
E4 allele or isoform with age or education were registered
in models in the presence of the primary variables.
Results
ApoE genotype and phenotype results were available for
3564 (95%) of the 3734 men who participated at the
1991–1993 examination. Data are presented based on
individuals (Table 1) and on isoforms or alleles (two per
person, n 5 7128; Table 2). As expected, the most common
ApoE type was 3-3. Distinguishing the probability of a
phenotype-genotype nonconcordance according to iso-
forms, alleles, or individuals is important both for assess-
ing the clinical utility of the two methods and for under-
standing the biological meaning of such nonconcordance.
Of participants with genotype 3-3, 90% were also pheno-
typed as 3-3. Of participants with phenotype 3-3, 94%
were also genotyped as 3-3. The discrepancies were
largely attributable to an excess of the E2 isoform (Table
2A). When calculated as a conditional probability, 43% of
ApoE phenotyped as 2 were genotyped as 3 (Table 2B).
The probability of an ApoE2 phenotype among persons
genotyped as 3 was 4% (Table 2C).
Frequencies of AD for each ApoE type are shown in
Table 3. Of 17 men with the 4-4 phenotype and 16 men
with the 4-4 genotype, 3 were found to have AD, com-
pared with a computed expected number of 0.5 AD cases.
Table 4 shows the association with AD of ApoE genotype
Table 1. Phenotype vs genotype of 2-, 3-, 4-allele/isoform
of ApoE, per person.
Phenotype
Genotype
2-2 2-3 2-4 3-3 3-4 4-4 Total
2-2 5 7 4 2 0 0 18
2-3 2 261 2 227 5 0 497
2-4 1 2 28 0 1 0 32
3-3 0 26 3 2332 107 0 2468
3-4 0 1 0 32 497 2 532
4-4 0 0 0 0 3 14 17
Total 8 297 37 2593 613 16 3564
Table 2. Phenotype vs genotype of ApoE, per gen (twice




2 3 4 Total
2 317 244 4 565
3 32 5814 119 5965
4 1 38 559 598
Total 350 6096 682 7128
B. Conditional probability of genotype, given phenotype (to
be read rowwise)
Genotype
Phenotype 2 3 4 Total
2 0.56 0.43 0.007 1.0
3 0.005 0.97 0.02 1.0
4 0.002 0.06 0.94 1.0
C. Conditional probability of phenotype, given genotype (to
be read columnwise)
Genotype
Phenotype 2 3 4
2 0.91 0.04 0.006
3 0.09 0.95 0.17
4 0.003 0.006 0.82
Total 1.0 1.0 1.0




No AD AD %AD No AD AD %AD
2-2 18 0 0 8 0 0
2-3 490 7 1 291 6 2
2-4 30 2 6 36 1 3
3-3 2397 71 3 2526 67 3
3-4 511 21 4 586 27 4
4-4 13 4 24 12 4 25
Total 3459 105 3 3459 105 3
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and phenotype using logistic regression adjusted for age
and education. The OR for ApoE4 heterozygotes and AD
was similar for genotype and phenotype and was approx-
imately a twofold excess risk (P ,0.01) over non-ApoE4
individuals. There was similarity in AD risk association
for genotype and phenotype comparisons of ApoE4 ho-
mozygotes with an OR of ;14 (P ,0.001). For ApoE2, a
moderate protective effect was evident with an OR of
;0.5 (P .0.09), similar for phenotype and genotype.
There were insufficient 2-2 cases to determine whether a
dose–response relationship existed with homozygous
ApoE2 (expected numbers ’0.5; found, none). In all
models, the OR estimating the increasing occurrence of
AD with a single year of age was 1.24, whereas the OR of
AD for a single year of schooling completed was 0.96.
The increased frequency of AD among ApoE4 ho-
mozygotes (OR 5 14.7) was higher than expected from an
independent heterozygote ApoE4 effect [(OR 5 2.0)2 5
4.0]; the square of the upper confidence limit of the OR of
e4 heterozygotes (3.22 5 10.2) is less than the point
estimate of the e4 homozygotes (14.7), and conversely, the
root of the lower confidence limit of the OR of e4
homozygotes (=4.0 5 2.0) is equal to the point estimate of
the e4 heterozygotes (2.0). This suggests that homozygos-
ity is associated with a higher risk of AD than two
independent alleles (at a 5% significance level). This
“recessive” character of the ApoE4 gene risk was equally
apparent when isoform typing was used.
The association of ApoE (both 2 and 4, both homo- and
heterozygous) with AD appeared to be almost indepen-
dent of age. The OR without age adjustment was 12.2
(3.8–39.0) for E4 homozygotes and 12.0 (3.7–38.8) for e4
homozygotes. (For the ORs with adjustment, see Table 4.)
The independence of the effects of age and ApoE4 was
further supported by the introduction of an interaction
term, which was nonsignificant (P ,0.38 for E4 homozy-
gotes and P ,0.36 for e4 homozygotes). This finding
points to at least partially different mechanisms underly-
ing the influences of age and ApoE on the development of
AD, and suggests that the increased occurrence of AD
with ApoE4 positivity is generally constant across the age
range in this population (71–93 years).
Because of this age independence, the strength of the
association of AD with ApoE4 can be expressed in a
“corresponding” age difference (Table 4). Estimated from
logistic regression, ApoE4 heterozygosity confers on an
individual a probability of having AD approximating that
of an otherwise similar 3-3 individual who is 3 years
older. Similarly, an ApoE4 homozygous person has a
probability of AD similar to that of a 3-3 person who is 12
years older.
Despite the considerable and significant OR (;14) for
4-homozygosity and AD, the effect of age in predicting
AD is quite dominant. It is useful, therefore, to compare
the number of additional cases of AD one might predict
using ApoE4 status in addition to age and education,
compared with age and education only. The classification
table of the logistic regression, presented in the form of a
so-called ROC curve (38 ) in Fig. 1, shows the trade-off of
sensitivity against specificity. The two ROC curves are
almost identical. In our study population, given a “fixed”
sensitivity of 66.7%, the specificity in predicting AD
increased from 83.0% to 83.3% when ApoE4 status was
included in the logistic model in addition to age and
education. Thus, in population screening, ApoE4 status
contributes little to predicting dementia, if age and edu-
cation are known.
Table 4. Association of ApoE alleles/isoforms with AD.
Confidence interval
ORa CI Years differenceb
Phenotype
2 homozygous –c
2 heterozygous 0.5 0.3–1.1 22.88
4 heterozygous 1.9 1.1–3.0 2.90
4 homozygous 14.2 3.9–51.6 12.24
Genotype
2 homozygous –c
2 heterozygous 0.6 0.3–1.4 22.16
4 heterozygous 2.0 1.3–3.2 3.23
4 homozygous 14.7 4.0–53.6 12.36
a OR calculated by logistic regression, adjusting for age and education.
b Years difference: the risk for AD corresponds to the risk of a ApoE 3-3 person
who is x years older.
c No occurrences of 2-2 allele/isoform in AD group; OR considered “low” and
confidence interval “wide”.
Fig. 1. ROC curve of AD prediction by a logistic model adjusted for age
and education, without and with ApoE4 status.
The specificity (spec) and sensitivity (sens) of the prediction by the logistic model
are shown. The predicted outcome (AD or no AD) is compared with the “true”
outcome. Solid line, prediction by age and education only; dashed line, prediction
by homo- and heterozygous e4 status in addition to age and education.
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Discussion
There is growing interest in identifying and using genetic
polymorphisms for disease risk, including risk for AD, in
the general population. This interest has been particularly
strong for ApoE4 in relation to AD. Although there has
been some endorsement of the use of genotyping for
dementia patients, population screening of asymptomatic
individuals has not been recommended (27 ). It is, how-
ever, important to distinguish among use for epidemio-
logical research, patient care, and population screening.
epidemiological studies
An important aspect of epidemiological research is the
discovery and modeling of risk associations. An impor-
tant conclusion of our study is that the phenotypes and
genotypes of ApoE2 and ApoE4 are associated with
similar magnitude with AD: ApoE2 appears to be mod-
erately protective and ApoE4 is a risk factor. The robust-
ness of these relationships supports the use of phenotyp-
ing, especially when DNA specimens are not available, as
is the case in many large longitudinal population-based
studies. Confirmatory observations might also support
the use of specimens collected many years previously in
retrospective cohort studies. Such investigations might
add to existing knowledge of incidence of AD and
whether differential mortality related to the presence of
ApoE4 might distort subsequent relationships (39, 40).
However, for studies of ApoE2, considerable differences
in persons identified as “at risk” by genotyping or phe-
notyping must be kept in mind. It has yet to be established
whether the high frequency of ApoE2 phenotype-geno-
type nonconcordance we observed is specific to the Jap-
anese-American subjects in the HAAS or occurs in other
populations as well.
patient care
For specificity of characterization, the standard for patient
care has become the genotype, and this procedure is
recommended, especially because many laboratories are
offering this determination. In addition, in the future it is
likely that there will be other polymorphisms best studied
with DNA, and these will completed in conjunction with
ApoE determinations. Although the association of ApoE4
with a risk for AD is similar for genotype and phenotype,
the remaining individual nonconcordance is not to be
neglected, and—as is usual in clinical situations—the
clinician must consider the gained information in the
context of all available information bearing on the diag-
nosis.
population screening
Population screening for AD would involve persons with-
out any known predisposition for this condition. The
expected prevalence of AD would be mainly dependent
on the age composition of the population and would be
rather low. In our population sample of men 71–93 years
of age, screening for AD by means of ApoE would not
have been fruitful, except for identification of the limited
number of ApoE4-4 persons. In the general population,
use of ApoE status in addition to the freely available
information on age and education only marginally im-
proves prediction, as demonstrated by the ROC curves.
Furthermore, screening is at present—without a fairly
effective therapy for AD—not justified.
what might explain the high frequency of
phenotype-genotype nonconcordance in this
population?
Although major discrepancies between ApoE phenotypes
and genotypes have been reported previously, the extent
of nonconcordance has varied dramatically. The initial
descriptions of phenotype-genotype nonconcordance
were focused on their associations with diabetes and
hyperglycemia, leading to speculation that a glucose-
driven posttranslational modification of the protein might
lead to alteration in the band pattern on isoelectric focus-
ing and ultimately to errors in typing (23–26). For the
most part, these observations have not been confirmed,
and the glycation of the molecule appears an unlikely
cause for substantial nonconcordance. A second possibil-
ity is clerical or laboratory error, occurring by chance (22 ).
A third possibility, as yet not demonstrated to be an
important cause of phenotype-genotype nonconcordance,
is that there are rare genetic polymorphisms associated
with ApoE2 that affect protein expression and/or alter the
primary structure of the gene product. Some reports of
“rare” polymorphisms have appeared, notably in the
Japanese population (ApoE-e7, ApoE-E1, ApoE-E5,
ApoE-E7) (41–43), but unusual mutations have also been
reported that cause an ApoE-e4/E4 discrepancy with
usual assessment methods (44 ). Finally, “normal” varia-
tions in test reproducibility may explain part of the
nonconcordance; these may become visible especially in
studies with large numbers of subjects. In fact, there is a
point to be made for routinely genotyping DNA in
duplicate, as soon as “cheaper” techniques allow the extra
effort.
etiology
Our finding of the independence of risk for AD associated
with age and ApoE (in a group of men over age 70) may
reflect the presence of AD and not its progress. Indepen-
dence was also found by others (19, 45). However, some
dependencies have been found in clinical case-control
studies with a wider age range (11, 46). It has also been
reported that the influence of ApoE4 may diminish rather
dramatically after age 80 (47 ). ApoE4 does not seem to be
related to the progress of AD (48–50), which is in contrast
to the association of ApoE with the progress of cognitive
impairment in similar age groups (51–53).
The choice of genotyping or phenotyping should also
be informed by the other correlates of ApoE type, espe-
cially as related to lipid metabolism. Before identification
of the relationship between ApoE4 and AD, most work
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with ApoE type related to cardiovascular disease and
lipid concentrations. Because this research goes back
several years and because of limitations in technology,
ApoE serum proteins were measured either directly or in
the VLDL subfraction (22 ). As genotyping became avail-
able, there were some attempts to compare results. In one
such comparison, serum triglyceride concentrations were
higher in the phenotyped ApoE2 subgroup compared
with the genotyped designation (22 ). The reasons for this
discrepancy were unclear. The possibility that unrecog-
nized genotypes or different intermediary processes
might affect physiologic and metabolic measurements has
been suggested (22 ). Such phenomena could vary with
ethnicity, comorbidity, or other factors.
The observation of Lahoz et al. (22 ) that many ApoE
phenogenotype-genotype discrepancies could be attrib-
uted to errors in labeling or handling must not be mini-
mized. When ApoE typing is important for the care or
diagnosis of an individual, only very low laboratory error
is tolerable. When typing is done as part of epidemiologic
research, the identification of true phenotype-genotype
differences may well lead to a better understanding of
several illnesses, including AD, atherosclerosis, and dia-
betes. The importance of reliable typing for research or
clinical purposes is obvious. Although duplicate testing
has rarely been done for genetic assays, this or some other
method for detecting test inconsistencies could ultimately
be an important quality-control strategy for laboratories
conducting such tests.
In conclusion, the HAAS provided a valuable opportunity
to evaluate various aspects of the use of ApoE phenotyp-
ing and genotyping in a population-based epidemiologi-
cal study. In this specific population, either genotyping or
phenotyping was adequate for determining associations
of ApoE4 with AD. Genotype and phenotype showed
similar associations, although mild discrepancies for
ApoE4 and substantial discrepancies for ApoE2 produced
some differences in which individuals were identified.
The effect of age and ApoE status on AD presence
appeared to rather independent. Our findings indicate
that the use of ApoE status for screening of the general
population would provide only minimal improvement in
prediction of cases over the use of education and age only.
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